gastric cancer
Oncology · 2011–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| durvalumab Perioperative treatment (neoadjuvant and adjuvant) of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma who are eligible for… | Mar 2026 | Recommended with restriction | input received Rare Cancers Australia |
| zolbetuximab First-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose… | Mar 2025 | Deferred | input received Rare Cancers Australia · Medical Oncology Group |
| trastuzumab deruxtecan Treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in patients who have progressed… | Nov 2025 | Deferred | input received Rare Cancers Australia · Medical Oncology Group |
| nivolumab First-line treatment of patients with non-HER2 positive advanced or metastatic gastric cancer, gastro-oesophageal junction cancer, or oesophageal… | Mar 2022 | Not recommended | 2 individuals Pancare Foundation · Medical Oncology Group |
| nivolumab First-line treatment of patients with non-HER2 positive advanced or metastatic gastric cancer, gastro-oesophageal junction cancer, or oesophageal… | Nov 2021 | Not recommended | 2 individuals Pancare Foundation · Medical Oncology Group |
| ramucirumab Treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and… | Jul 2019 | Not recommended | unclear |
| trastuzumab HER2-positive early, locally advanced and metastatic breast cancer, and HER2-positive metastatic gastric cancer. | Jul 2019 | Recommended with restriction | none received |
| trastuzumab HER2-positive early, locally advanced and metastatic breast cancer, and HER2-positive metastatic gastric cancer. | Mar 2019 | Recommended | none received |
| trifluridine with tipiracil Treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have been previously treated with… | Nov 2019 | Recommended with restriction | input received Medical Oncology Group |
| ramucirumab Advanced or metastatic gastric adenocarcinoma or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine… | Mar 2018 | Recommended with restriction | input received Medical Oncology Group |
| trastuzumab Treatment of HER2 positive, metastatic (stage IV) adenocarcinoma of the stomach or gastro-oesophageal junction in patients who have not received prior… | Jul 2015 | Recommended with restriction | none received |
| trastuzumab Treatment of HER2-positive advanced (stage III or IV) adenocarcinoma of the stomach or gastro-oesophageal junction in patients who have not received prior… | Nov 2012 | Deferred | unclear |
| trastuzumab Treatment of HER2-positive advanced adenocarcinoma of the stomach or gastro-oesophageal junction in patients who have not received prior anti-cancer treatment… | Jul 2011 | Not recommended | no section in document |
Who spoke
Medical Oncology Group · Rare Cancers Australia · Pancare Foundation
What the PBS pays
$424M in government benefit over 2024–25, across 116,004 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| durvalumab | $175.6M |
| trastuzumab deruxtecan | $98.9M |
| nivolumab | $85.2M |
| trastuzumab | $54.3M |
| trifluridine with tipiracil | $9.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 9 technologies for this condition, recommending 5 and declining 3. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| durvalumabDurvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma | TA1160 | recommended restricted | 2026-06 |
| zolbetuximabZolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma | TA1046 | not recommended | 2025-03 |
| pembrolizumabPembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma | TA997 | recommended restricted | 2024-08 |
| pembrolizumabPembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma | TA983 | not recommended | 2024-06 |
| trastuzumab deruxtecanTrastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) | TA879 | terminated | 2023-04 |
| nivolumabNivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma | TA857 | recommended restricted | 2023-01 |
| trifluridine tipiracilTrifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments | TA852 | recommended restricted | 2022-12 |
| ramucirumabRamucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy | TA378 | not recommended | 2016-01 |
| capecitabineCapecitabine for the treatment of advanced gastric cancer | TA191 | recommended | 2010-07 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| epirubicinEPIRUBICIN ACCORD epirubicin hydrochloride 10mg/5mL concentrated injec | 1992 | 5 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 11 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.